Transaction DateRecipientSharesTypePriceValue
28th May 2020Richard S Serbin25,000Exercise of derivative$3.96$99,000.00
28th May 2020Richard S Serbin17,500Open or private sale$18.03$315,525.00
28th May 2020Richard S Serbin7,500Open or private sale$18.00$135,000.00
26th May 2020Eugene Durenard25,000Open or private sale$18.26$456,500.00
20th May 2020Eugene Durenard25,000Exercise of derivative$0.71$17,750.00
20th May 2020Eugene Durenard25,000Exercise of derivative$3.96$99,000.00
20th May 2020Eugene Durenard25,000Open or private sale$18.40$460,000.00
19th May 2020Richard S Serbin25,000Open or private sale$18.50$462,500.00
19th May 2020Richard S Serbin25,000Exercise of derivative$0.71$17,750.00
6th December 20182030 Capital, Llc America1,134,898Sale back to the issuer$0.01$11,348.98
Co Diagnostics
Co Diagnostics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.


Co-Diagnostics, Inc. is a molecular diagnostics company. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013.


Ticker: CODX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1692415
Employees: 23
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals